Pharmaceutical Executive, Oct 1, 2013 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Oct 1, 2013
Features
Field Force Evolution: Adapting to a New Ecosystem
By Ben Comer
Environmental changes on all sides of professional sale are forcing biopharmaceutical companies to select for new traits in the makeup of the field force function.
Not Much Ado About the ACA
By Mason Tenaglia
With key provisions of the Affordable Care Act set to launch this month, industry veteran Mason Tenaglia says the impact all depends on what you sell and where you sit.
12th Annual Pharmaceutical Industry Audit
By Bill Trombetta
With revenues down and margins squeezed by a realigning payer pool, the power to price above the market is the ticket to the top—no discounts allowed.
Country Report
Country Report: UAE
Rumor has it the BRIC palace is crumbling. Perhaps that's overdramatic, but at the very least the BRIC oven is cooling off. Where to now? The United States and Europe remain in a state of languid stagnation, while Asia and Africa are largely addressing basic healthcare needs with low-cost generic medicine.
Column
Brand-Generic Wars Heat Up
By Jill Wechsler
Tension mounts over biosimilars, co-pay coupons, trade, and testing.
Using Data to Influence Behavior and Predict Outcomes
By Ben Comer
Predictive analysis has been used to great effect in the finance, tech, retail, and telecoms industries. Can it also improve decision-making and health outcomes in life sciences?
Special Delivery
By Jeff Baker
New drug delivery mechanisms and devices are an opportunity to build relationship with the ultimate customer: the patient.
Market Access is Dead
By John Glasspool
Patient access is the new driver of change and progress in healthcare marketing, says a senior industry player in market development.
Big Pharma's Newest Cost Center
By Hae-Won Min Liao , Michele Tagliaferri
As the burden of promotional disclosure expands beyond US shores, understanding the rules and then controlling the cost of compliance is a strategic necessity.
Divining the Future of Devices
By Reflector
European efforts to crack down on safety and pricing issues in the marketing of medical devices may portend long-term problems for Big Pharma.
Pay for Delay?
By Søren Zinck
Europe follows the United States with a harsh new spotlight on agreements that slow generic entry for medicines losing exclusivity.
From the Editor
Taking Stock: Notes on the Industry Audit
By William Looney
Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."

ADVERTISEMENT

Click here